Navigation Links
Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
Date:9/28/2007

CALGARY, Sept. 28 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced that an oral presentation covering interim results from a U.K. Phase Ia/Ib combination REOLYSIN(R) and radiation clinical trial for patients with advanced or metastatic cancers is scheduled to be presented at the National Cancer Research Institute (NCRI) conference on October 2, 2007 in Birmingham, U.K. The presentation, entitled "Biological Approaches to Radiosensitisation: Viruses, Gene Therapy and Novel Radiosensitisers" will be presented by Dr. Kevin Harrington of The Institute of Cancer Research, London and one of the principal investigators for the trial. The conference runs from September 30 through October 3, 2007 in Birmingham, U.K.

"We are very pleased with the results of this trial to date," said Dr. Brad Thompson, President and CEO of Oncolytics. "We continue to evaluate the data and look forward to announcing final results."

To date, 22 patients have been treated with 15 having completed the study. Five patients withdrew from the study, and two patients are still on study.

A total of 11 patients in the Ia portion of the trial received two intratumoural treatments of REOLYSIN(R) at dosages of 1x10(8), 1x10(9), or 1x10(10) TCID(50) with a constant localized radiation dose of 20 Gy given in five fractions. Of these 11 patients, three patients (oesophageal, squamous skin carcinoma and squamous cell scalp) experienced significant partial responses.

One month following treatment, the oesophageal patient experienced a 28.5% reduction in the target tumour, with stable disease noted in four, non-treated tumours. At two and three months, the target tumour had shrunk 64%, with stable disease continuing in the four non-treated tumours, including a 15% volume reduction in non-treated mediastinal disease that was maintained for more than six months. The squamous skin cancer patient experienced a 50% reduction in the t
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. The state of global biotech: An Ernst & Young perspective
2. Olympics of biotechnology has international flavor
3. Biotech officials praise focus of new venture fund
4. Getting noticed in Genetown: Wisconsin biotech on display
5. Madison biotech NimbleGen files for IPO; one of states best-funded firms
6. Wisconsin biotech firm receives $107K NIH grant
7. Biotech executive books a career flight thats closer to home
8. Manufacturing partnership will move into biotech and biomedical spaces
9. Wisconsin wont get Georgia biotech without a fight
10. The 10 biggest events shaping biotech in 2006
11. Gala Biotech among companies sold for $3.3 billion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015  Pfenex Inc. (NYSE MKT: ... of biosimilar therapeutics, today announced that it will be ... Marquis on March 2 nd at 3pm PST. Patrick ... a panel discussing the current state of the biosimilar ... . For more information on CALBIO ...
(Date:2/26/2015)... -- S&P Capital IQ (MHFI) announced today that it ... Therapeutics Holdings Inc . MabVax Therapeutics ... focused on the development of vaccine and antibody-based therapies ... cancer. MabVax has discovered a pipeline of human monoclonal ... by patients who have been immunized against targeted cancers. ...
(Date:2/26/2015)... Feb. 26, 2015   Regulus Therapeutics Inc . ... the discovery and development of innovative medicines targeting microRNAs, ... President and Chief Executive Officer of Regulus, will present ... th Annual Healthcare Conference on Wednesday, March 4, ... held at the Boston Marriott Copley Place.  ...
(Date:2/26/2015)... IRVINE, Calif. , Feb. 26, 2015 /PRNewswire/ ... of age-defying aesthetic products for skin and hair ... Market Relations as agency of record for investor ... continues to improve our distribution, sales and diversification ... activities to current and prospective shareholders," stated Ali ...
Breaking Biology Technology:S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 2NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 3
... of Energy,s Lawrence Berkeley National Laboratory and the ... world,s first all-integrated sensor circuit based on nanowire ... different crystalline materials. Their method can be used ... , Nanostructures made with specific chemical, electronic, ...
... Revenues - a record $35.5 million vs. $24.7 million in Q2 2007 ... - an increase of 43.4%, Q2 2008 Diluted Net Income per Share - ... ... Q2 2007 Q2 2008 New Bookings of $49.0 million vs. $34.5 million in Q2 2007, ...
... Conference, August 3-8, CHICAGO, Aug. 4 Criminal ... to reduce the spread of the virus.,Instead, it increases ... burdening women and other vulnerable groups who,are unable to ... violence,according to a commentary in the August issue of ...
Cached Biology Technology:A first in integrated nanowire sensor circuitry 2A first in integrated nanowire sensor circuitry 3A first in integrated nanowire sensor circuitry 4eResearchTechnology Reports Second Quarter 2008 Results 2eResearchTechnology Reports Second Quarter 2008 Results 3eResearchTechnology Reports Second Quarter 2008 Results 4eResearchTechnology Reports Second Quarter 2008 Results 5eResearchTechnology Reports Second Quarter 2008 Results 6eResearchTechnology Reports Second Quarter 2008 Results 7eResearchTechnology Reports Second Quarter 2008 Results 8eResearchTechnology Reports Second Quarter 2008 Results 9JAMA Commentary Opposes Criminal Punishment for HIV Exposure/Transmission 2JAMA Commentary Opposes Criminal Punishment for HIV Exposure/Transmission 3
(Date:1/22/2015)... /PRNewswire/ - Today, FindBiometrics, the leading source of biometrics industry news, ... website design. "When we launched FindBiometrics 12 years ... O,Neill , founder and CEO of FindBiometrics. "Now it,s maturing ... the key players on a very broad scale.  We are ...
(Date:1/22/2015)... , Jan. 16, 2015  A man-made form of ... and other mental capabilities in adults with mild cognitive ... study led by researchers at Wake Forest Baptist Medical ... diagnosed with amnesic mild cognitive impairment (MCI) or mild ...
(Date:1/22/2015)... , Europe,s most prestigious innovation ... to present a video retrospective of the most exciting and innovative ... Toumazou and Sophie Wilson   A different ...   Starting on 22 January 2015 on   http://www.epo.org/european-inventor   ...
Breaking Biology News(10 mins):Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3
... have identified an ,on/off, switch in a type of cancer ... germ cell tumours,. The research was published today, 01 August, ... cell tumours arise in sperm- or egg-forming cells and usually ... cancerous tumours are seen in patients of all ages, both ...
... Chanel, UC Santa Barbara,s corpse flower, has finally spread her ... between rotting flesh and Limburger cheese. "It,s disgusting," said UCSB ... Other visitors said Chanel smelled like "French cheese" or ... technician in the Life Science Computing Group at UCSB said, ...
... shows that rubber slat mats could improve swine health. In ... , researchers in Europe studied how different types of flooring ... According to the researchers, flooring is one of the main ... Locomotory problems can be caused by joint injuries or by ...
Cached Biology News:Scientists discover a molecular 'switch' in cancers of the testis and ovary 2Chanel, UCSB's corpse flower, blooms and causes a big stink 2Chanel, UCSB's corpse flower, blooms and causes a big stink 3Rubber slat mats could improve animal well-being 2
Mouse monoclonal antibody raised against a partial recombinant NEK2. NCBI Entrez Gene ID = NEK2...
... DS-L2 imaging controller is a successor of ... allows users to comfortably observe, record and ... features an 8.4 inch LCD (XGA) monitor ... Nikon cameras including the DS-Fi1 , DS-5Mc ...
... NightOWL is a dedicated imaging system for ... light due to pixel size. Equipped with ... level light in animals or plants in ... circadian rhythm or Western blots. NightOWL is ...
... NightOWL is a dedicated imaging system ... size. Equipped with a very sensitive camera ... or plants in tumor research, infectious disease ... Western blots. NightOWL is the only imager ...
Biology Products: